Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis
Status:
Terminated
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The purposes of the study is to determine if LiRIS®, an investigational drug-delivery system,
is safe and tolerable in women with Interstitial Cystitis (IC), and to evaluate any change in
IC symptoms following LiRIS administration.